An Open Label Evaluation of the Single Dose Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2016
Price : $35 *
At a glance
- Drugs Delafloxacin (Primary)
- Indications Gonorrhoea; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
- Focus Pharmacokinetics
- Sponsors Melinta Therapeutics
- 29 Aug 2016 Results published in the Journal of Clinical Pharmacology
- 09 Oct 2015 Results of this trial were presented at ID Week, the annual meeting of both the Infectious Disease Society of America and the Society for Healthcare Epidemiology of America, according to a Melinta Therapeutics media release.
- 29 Apr 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.